{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=6&q=advanced+solid+tumors", "query": { "q": "advanced solid tumors", "condition": "Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 5924, "total_pages": 593, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=7&q=advanced+solid+tumors&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=5&q=advanced+solid+tumors&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:10:16.119Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05836324", "title": "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "INCA33890", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "ADG126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 570, "start_date": "2023-07-24", "completion_date": "2029-05-03", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 11, "location_summary": "Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836324" }, { "nct_id": "NCT00047242", "title": "UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-08-09", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047242" }, { "nct_id": "NCT04316169", "title": "Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Hydroxychloroquine 200 mg", "type": "DRUG" }, { "name": "Faslodex", "type": "DRUG" }, { "name": "Anastrazole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Hydroxychloroquine 400 mg", "type": "DRUG" }, { "name": "Hydroxychloroquine 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-21", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2022-12-23", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04316169" }, { "nct_id": "NCT00698841", "title": "Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2009-02", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 15, "location_summary": "Muscle Shoals, Alabama • Casa Grande, Arizona • Corona, California + 12 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698841" }, { "nct_id": "NCT03761017", "title": "MGD019 DART® Protein in Unresectable/Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Non Small Cell Lung Cancer", "Prostate Cancer Metastatic", "Cutaneous Melanoma", "Colorectal Cancer", "Advanced Cancer", "Solid Tumor, Adult" ], "interventions": [ { "name": "Lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2018-12-12", "completion_date": "2025-01-27", "has_results": false, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 17, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761017" }, { "nct_id": "NCT04257617", "title": "A Trial of ZL-1201 in Subjects With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "ZL-1201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zai Lab (Shanghai) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-05-11", "completion_date": "2023-01-19", "has_results": false, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04257617" }, { "nct_id": "NCT05036291", "title": "A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "NB004 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ningbo Newbay Technology Development Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-01", "completion_date": "2025-10-10", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 2, "location_summary": "New Orleans, Louisiana • Houston, Texas", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05036291" }, { "nct_id": "NCT02248090", "title": "AZD9496 First Time in Patients Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ER+ HER2- Advanced Breast Cancer" ], "interventions": [ { "name": "AZD9496", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2014-10-22", "completion_date": "2019-04-03", "has_results": false, "last_update_posted_date": "2019-06-24", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 3, "location_summary": "Sarasota, Florida • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02248090" }, { "nct_id": "NCT03728361", "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade I Neuroendocrine Carcinoma", "Grade II Neuroendocrine Carcinoma", "Grade III Neuroendocrine Carcinoma", "Metastatic Neuroendocrine Carcinoma", "Neuroendocrine Carcinoma", "Recurrent Small Cell Lung Carcinoma", "Refractory Small Cell Lung Carcinoma", "Lung Cancer Stage IV", "Large Cell Neuroendocrine Carcinoma", "Neuroendocrine Tumors", "Small Cell Lung Cancer Metastatic", "Small-cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dwight Owen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-12-31", "completion_date": "2025-12-02", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 2, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03728361" }, { "nct_id": "NCT04410224", "title": "Study of ASN004 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ASN004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kirilys Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-04-08", "completion_date": "2024-05-08", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-10-13T23:10:16.119Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Austin, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410224" } ] }